Biodiem (BDM) has just announced very encouraging results from trials of its synthetic antibiotic replacement for poultry.
If the results are borne out in further testing, it suggests significant savings are achievable for poultry growers in addition to meeting concerns about weakened human disease resistance as a result of antibiotic use in poultry feed.
The market likes it, even though the announcement was not considered market sensitive.
I've held BDM for a while because of its interesting IP portfolio (especially the potential of its LAIV for potential epidemic flu strains like bird flu) but have been dismayed to see the SP slump dramatically since its IPO. Maybe the tide is now turning...
Worth checking out IMO but scarcely a market darling. It needs a big pharma deal to set it back on track. With results like today's announcement, that event may now be a little closer. Certainly it owns the rights to some interesting IP.
